Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VAXZEVRIA Intramuscular Injection Specific Use Result Study for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

NCT05084755 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05084755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05084755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VAXZEVRIA Intramuscular Injection Specific Use Result Study for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Terminated
Start date
November 11, 2021
Completion date
September 16, 2022
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of infectious disease caused by sars-cov-2